Riskpilot← Back to searchSign inGet full access2care4 Generics ApS
APSActiveCVR 36960566Stenhuggervej 12Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201533 employeeswww.2care4generics.dk
Revenue 2024
DKK 58,2M
-21% vs 2023
EBITDA margin
47.9%
-41% vs 2023
Equity ratio
60.7%
Financial strength
Net profit 2024
DKK 17,2M
-46% vs 2023
| Revenue | DKK 58,2M | -21% |
| EBITDA | DKK 27,8M | -41% |
| Net profit | DKK 17,2M | -46% |
| Total assets | DKK 129,7M | -24% |
| Equity | DKK 78,7M | -9% |
| Employees | 33 | — |
Legal name
2care4 Generics ApS
CVR number
36960566
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10. juli 2015
Share capital
DKK 50.000
Employees
33 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at udvikle, importere, producere, forhandle og eksportere lægemidler samt anden dermed i naturlig forbindelse stående virksomhed.
Address
Stenhuggervej 12
Phone
+4576101500
Email
info@2care4generics.dk
Website
www.2care4generics.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.053 | -1.519 | 3.261 | 7.989 | 32.852 | 55.863 | 75.691 | 73.414 | 58.190 |
| Staff expenses | -4.022 | -4.849 | -5.167 | -5.596 | -11.480 | -14.423 | -21.387 | -26.457 | -30.346 |
| EBITDA | -5.075 | -6.368 | -1.906 | 2.392 | 21.372 | 41.440 | 54.304 | 46.957 | 27.844 |
| Depreciation & amort. | -15 | -1.088 | -1.326 | -2.469 | -2.190 | -5.280 | -9.655 | -5.797 | -5.788 |
| EBIT | -5.090 | -7.456 | -3.232 | -77 | 19.182 | 36.160 | 44.649 | 41.160 | 22.056 |
| Net financials | 419 | -269 | -481 | -731 | 73 | 96 | -377 | -678 | -51 |
| Profit before tax | -4.671 | -7.725 | -3.713 | -808 | 19.255 | 36.256 | 44.272 | 40.482 | 22.005 |
| Tax | -1.028 | -1.699 | -816 | -208 | 3.540 | 7.174 | 9.674 | 8.918 | 4.812 |
| Net profit | -3.643 | -6.026 | -2.897 | -599 | 15.715 | 29.083 | 34.598 | 31.564 | 17.193 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11.266 | 12.384 | 21.273 | 35.417 | 72.433 | 127.774 | 170.991 | 170.370 | 129.738 |
| Equity | 6.357 | 330 | 434 | -166 | 15.549 | 44.632 | 74.230 | 86.544 | 78.737 |
| Long-term debt | 561 | 500 | 375 | 190 | 553 | 0 | 356 | 350 | 0 |
| Short-term debt | 2.638 | 9.677 | 17.783 | 30.939 | 49.083 | 74.974 | 87.742 | 74.806 | 40.878 |
| Total debt | 3.199 | 10.177 | 18.158 | 31.130 | 49.636 | 74.974 | 88.098 | 75.156 | 40.878 |
EBITDA margin
47.9%
This company
15.8%
Market median
+203% vs market
20162024
Equity ratio
60.7%
This company
38.2%
Market median
+59% vs market
20162024
Return on equity
21.8%
This company
18.4%
Market median
+18% vs market
20162024
Net profit margin
29.5%
This company
8.1%
Market median
+264% vs market
20162024
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20162024
Debt / equity
0.65×
This company
0.62×
Market median
+5% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-07-10 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TH Management | Management | 2024 | — | — |
UE Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
TB Management | Management | 2018 | — | — |
ES Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
HF Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
2care4 Group ApS | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HØJFELDT HOLDING ApS
2care4 Generics ApS Board members of 2care4 Generics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Hjarsbæk Rasmussen | Management | 0 companies |
| Ulrik Ernst Rasmussen | Chief Executive Officer | 0 companies |
| Torben Børsting | Management | 0 companies |
| Erik Sandberg | Chief Executive Officer | 0 companies |
| Henrik Fomsgaard-Knudsen | Chief Executive Officer | 0 companies |
| Henrik Bisgaard Jensen | Board of Directors | 0 companies |
| Toke Værndal | Board of Directors | 0 companies |